Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
In a randomized controlled study that included 27,654 patients with atherosclerotic disease, the addition of evolocumab to statin therapy lowered LDL levels by 59% (median, 30 mg/dL) from baseline compared with placebo and it conferred a 15% relative risk reduction in the primary outcome of CVD death, MI, or stroke
Novo Nordisk (DK) focuses on innovation and research, particularly in developing next-generation GLP-1 receptor agonists, while Eli Lilly (US) emphasizes strategic partnerships to expand its product offerings
"A brief history of antibiotics and select advances in their synthesis"
Our approach to aging healthily was to study the complications and declines in health that come with increasing years around the sun, and then try to find treatments for those, or minimize the risk factors
US$ 26.97
US$ 28.69
US$ 21.01
US$ 29.30
